Shane, who joins Asgard from Pieris Pharmaceuticals, now merged with NASDAQ-listed Palvella Therapeutics, will lead IND-enabling studies and clinical trials planning for Asgard’s lead asset AT-108.

Shane Olwell

During his thirteen years at Pieris, Shane played a pivotal role developing its diverse pipeline of clinical programs in immuno-oncology and respiratory diseases – progressing nine programs into the clinic. Prior to that he was Director of Research at AIM-listed Fusion Antibodies, building out its research team and establishing its technology platform. With over 60 intellectual property rights to his name, he is a recognized leader in drug development and a regular reviewer for prominent oncology and drug development journals. He holds a BSc in Biomedical Sciences and a PhD in Molecular Hematology from the University of Ulster, UK.

“Asgard’s in vivo cell reprogramming technology, based on the deep research and understanding of its founders, is a potentially transformative new form of cancer immunotherapy that is not only powerful but also indication-agnostic. I’m delighted to be joining the Company, whose science is backed by very strong data and whose team is supported by high calibre investors. I look forward to working to progress AT-108 towards the clinic and maximizing the potential of Asgard’s wider platform,” says Shane Olwill, Chief Development Officer of Asgard Therapeutics.